MST-0312 / Mestag Therap - LARVOL DELTA

MST-0312: Targeted LTBR agonist designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) for the treatment of solid tumors (AACR 2026) - "Abstract is embargoed at this time."

Late-breaking abstract • Oncology • Solid Tumor

MST-0312-1001: Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies (clinicaltrialsregister.eu) - P1 | N=42 | Not yet recruiting | Sponsor: Mestag Therapeutics Limited

New P1 trial • Oncology • Solid Tumor

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 (GlobeNewswire) - "Mestag Therapeutics...announced that it has been awarded a 'Transforming Cancer Therapeutics' grant from Innovate UK’s Cancer Therapeutics program of £1.5 million ($1.9 million) to accelerate the development of its MST-0300 antibody."

Financing • Oncology • Solid Tumor

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors (GlobeNewswire) - "Mestag Therapeutics...is today presenting data on its M300 program in a late-breaking poster session at the 2024 American Association for Cancer Research (AACR) meeting.....The presented data demonstrate that Mestag’s bispecific antibody co-engages fibroblast activated protein (FAP) and LTBR to conditionally activate LTBR and induce Tertiary Lymphoid Structures (TLS) in the tumor. In vivo data showed potent monotherapy efficacy as well as tumor regression in combination with tumor antigen or a checkpoint inhibitor."

Late-breaking abstract • Preclinical • Solid Tumor

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program (GlobeNewswire) - "Mestag Therapeutics...today announced the appointments of additional distinguished, world-leading advisors to guide the development of its lead program M300, a first-in-class antibody program designed to conditionally induce the formation of Tertiary Lymphoid Structures (TLS) in the tumor....The new appointments expand Mestag’s advisors and comprise a unique group of investigators with extensive experience in the development of novel cancer therapies and specific expertise in the field of TLS biology in cancer."

Preclinical • Oncology • Solid Tumor